Helen Milton
General Counsel bei VIRIDIAN THERAPEUTICS, INC.
Profil
Helen Milton is currently the Senior Vice President-Regulatory Affairs at Viridian Therapeutics, Inc. She previously worked as the Vice President-Global Regulatory Affairs & Quality at Keryx Biopharmaceuticals, Inc. from 2014 to 2017.
In 2020, she held the position of Senior VP-Regulatory Affairs & Quality at AMAG Pharmaceuticals, Inc. From 2021 to 2022, she worked as the Senior VP-Regulatory Affairs & Pharmacovigilance at Mallinckrodt Pharmaceuticals.
Dr. Milton obtained her undergraduate and doctorate degrees from The University of Liverpool.
Aktive Positionen von Helen Milton
| Unternehmen | Position | Beginn |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | General Counsel | 01.01.2023 |
Ehemalige bekannte Positionen von Helen Milton
| Unternehmen | Position | Ende |
|---|---|---|
| AMAG PHARMACEUTICALS, INC. | General Counsel | 01.12.2020 |
| KERYX BIOPHARMACEUTICALS | General Counsel | 01.05.2017 |
Ausbildung von Helen Milton
| The University of Liverpool | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
